Anumigilimab Clinical Trials (2026): 1 Studies for Sickle Cell Disease
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 Anumigilimab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Sickle Cell Disease) and 63 total planned enrollment. 1 Anumigilimab clinical trial is actively recruiting at 5 U.S. sites across 5 states. Most recent activity: NCT07224360 (Jun 2028).
Where to Participate: All Anumigilimab Trial Sites in the U.S. (5 sites across 5 states)
Every actively recruiting Anumigilimabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AR | UAMS Medical Center | Little Rock72202 | NCT07224360 | Map |
| FL | The Foundation for Sickle Cell Disease | Hollywood33023-6703 | NCT07224360 | Map |
| MD | Center for Cancer and Blood Disorders | Bethesda20817 | NCT07224360 | Map |
| MS | Southern Specialty Research | Flowood39232 | NCT07224360 | Map |
| NY | Jacobi Medical Center | The Bronx10461 | NCT07224360 | Map |
Anumigilimab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P2 | 1 | 1 |
Recruiting Anumigilimab clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07224360 | CSL324Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) | P2 | Sickle Cell Disease | 63 | Feb 2026 |
Anumigilimab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| CSL324 | NCT07224360 | P2 | recruiting | Sickle Cell Disease | 63 | — |
All Anumigilimab trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07224360 | CSL324 | Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) | P2 | recruiting | 63 | CSL Behring | Feb 2026 |
Anumigilimab clinical trials: frequently asked questions
- How many Anumigilimab clinical trials are there?
- 1 Anumigilimab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are Anumigilimab clinical trials recruiting in 2026?
- Yes — 1 Anumigilimab trial is actively recruiting in 2026, with 5 U.S. sites across 5 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Anumigilimab being studied for?
- Anumigilimab is being studied for Sickle Cell Disease. The trials are grouped by indication on this page.
- What phase is Anumigilimab in?
- Anumigilimab clinical trials span 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Anumigilimab clinical trials?
- The lead sponsor across the most Anumigilimab trials is CSL Behring. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Anumigilimabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: